WO2019088545A1 - Exosome kit and method for enhancing transdermal permeation of exosomes by using same - Google Patents
Exosome kit and method for enhancing transdermal permeation of exosomes by using same Download PDFInfo
- Publication number
- WO2019088545A1 WO2019088545A1 PCT/KR2018/012549 KR2018012549W WO2019088545A1 WO 2019088545 A1 WO2019088545 A1 WO 2019088545A1 KR 2018012549 W KR2018012549 W KR 2018012549W WO 2019088545 A1 WO2019088545 A1 WO 2019088545A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- exosome
- exosomes
- battery
- patch
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 202
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims description 56
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 208000017520 skin disease Diseases 0.000 claims abstract description 14
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 4
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 claims description 4
- 229910052744 lithium Inorganic materials 0.000 claims description 4
- 229910001416 lithium ion Inorganic materials 0.000 claims description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 4
- 229910052753 mercury Inorganic materials 0.000 claims description 4
- OJIJEKBXJYRIBZ-UHFFFAOYSA-N cadmium nickel Chemical compound [Ni].[Cd] OJIJEKBXJYRIBZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 238000010030 laminating Methods 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 230000002040 relaxant effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 238000011282 treatment Methods 0.000 abstract description 20
- 230000008591 skin barrier function Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 122
- 210000004027 cell Anatomy 0.000 description 34
- 238000009295 crossflow filtration Methods 0.000 description 29
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 27
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 27
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 27
- 239000002245 particle Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- 230000006872 improvement Effects 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 20
- 230000037303 wrinkles Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 16
- 208000003251 Pruritus Diseases 0.000 description 15
- 230000007803 itching Effects 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 210000000130 stem cell Anatomy 0.000 description 12
- 238000007654 immersion Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 9
- 239000000017 hydrogel Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 8
- 208000002874 Acne Vulgaris Diseases 0.000 description 8
- 206010000496 acne Diseases 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000011033 desalting Methods 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 230000037394 skin elasticity Effects 0.000 description 8
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 231100000321 erythema Toxicity 0.000 description 7
- 230000003020 moisturizing effect Effects 0.000 description 7
- 102100025222 CD63 antigen Human genes 0.000 description 6
- 238000011010 flushing procedure Methods 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 229960003160 hyaluronic acid Drugs 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 150000005846 sugar alcohols Polymers 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011026 diafiltration Methods 0.000 description 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000004745 nonwoven fabric Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 102100027221 CD81 antigen Human genes 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 206010040882 skin lesion Diseases 0.000 description 4
- 231100000444 skin lesion Toxicity 0.000 description 4
- 230000036560 skin regeneration Effects 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 230000037317 transdermal delivery Effects 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- -1 cellular debris Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000000909 electrodialysis Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 238000004627 transmission electron microscopy Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 0 CCCC(C(O)(O)OOC(C(*12)*1C(C1*)=*)C21N=O)C1(C(*)C*(C)C(C)(*)C(**)(C2)C2(**)C(*)C(*)C2*CC*C2)C(CCCC2C(*CC)C2)C*1 Chemical compound CCCC(C(O)(O)OOC(C(*12)*1C(C1*)=*)C21N=O)C1(C(*)C*(C)C(C)(*)C(**)(C2)C2(**)C(*)C(*)C2*CC*C2)C(CCCC2C(*CC)C2)C*1 0.000 description 2
- 208000035484 Cellulite Diseases 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000032541 Epidermal naevus Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010027145 Melanocytic naevus Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007256 Nevus Diseases 0.000 description 2
- 206010049752 Peau d'orange Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036232 cellulite Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000008151 electrolyte solution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000035990 intercellular signaling Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000013469 resistive pulse sensing Methods 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 210000004706 scrotum Anatomy 0.000 description 2
- 210000002955 secretory cell Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- BTVWZWFKMIUSGS-UHFFFAOYSA-N 2-methylpropane-1,2-diol Chemical compound CC(C)(O)CO BTVWZWFKMIUSGS-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010064729 Dark circles under eyes Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 description 1
- 206010046742 Urticaria contact Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000012996 alamarblue reagent Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 206010071572 autoimmune progesterone dermatitis Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002583 cell-derived microparticle Anatomy 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000011035 continuous diafiltration Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 238000011036 discontinuous diafiltration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 102000057640 human CD63 Human genes 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 208000002440 photoallergic dermatitis Diseases 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
Definitions
- the present invention relates to an exosomal kit for the percutaneous permeation enhancement of exosomes comprising a mask pack, a mask sheet or a patch applied or immersed with a composition comprising an exosome as an active ingredient, and an iontophoresis device will be.
- the present invention also relates to a method for enhancing transdermal permeability of exosome and its application, which enables the exosome to pass through the skin barrier effectively and to be deeply transferred into the skin using the exosome kit.
- the skin has a three-layer structure of epidermis, dermis, and subcutaneous fat.
- the stratum corneum of the epidermis which is located at the outermost part of the skin, suppresses moisture evaporation of the skin and acts as a skin barrier.
- the skin barrier of the stratum corneum has a problem of impairing the penetration of the active ingredient when the functional cosmetic or the medicinal product is applied to the skin, thereby deteriorating the efficacy of the functional cosmetic or the medicinal product.
- a transdermal delivery system is an effective ingredient applied to the surface of the skin to easily pass through the skin barrier and deliver it deeply into the skin.
- transdermal delivery systems include liposomes. Liposomes are composed of lipid bilayers that are structurally similar to cell membranes or intercellular lipids of the stratum corneum, so they can be fused with cell membranes, effectively transferring the active ingredients inside the liposomes into the skin. Artificially synthesized liposomes, however, have limited stability and limited skin penetration.
- Ethosomes are made by dissolving phospholipids in ethanol known as skin permeation enhancers. Ethanol ethanol weakens the intercellular lipid membranes of the skin's horny layer, increasing the skin's absorption rate of the active ingredient and making the membrane of the endoplasmic reticulum itself flexible. This feature allows the etosome to deliver effective ingredients to the deeper and deeper part of the active ingredient in the skin.
- ethosomes also have problems such as particle aggregation due to curing of nanoparticles and layer separation phenomenon.
- exosome which has intercellular signal transduction
- Extracellular vesicles Cells release various membrane-type vesicles in the extracellular environment, and these release vesicles are commonly referred to as extracellular vesicles (EVs).
- the extracellular endoplasmic reticulum is sometimes referred to as cell membrane-derived endoplasmic reticulum, ectosomes, shedding vesicles, microparticles, exosomes and, in some cases, differentiated from exosomes.
- Exosome is an endoplasmic reticulum of several tens to several hundreds of nanometers in size, composed of double lipid membranes identical to the cell membrane structure, and contains proteins, nucleic acids (mRNA, miRNA, etc.) called exosomal cargo inside.
- Exosomal cargo contains a wide range of signaling factors, which are known to be specific for cell types and differentially regulated by the environment of the secretory cells.
- Exosome is an intercellular signaling mediator that is secreted by the cell, and various cell signals transmitted through it regulate cell behavior including activation, growth, migration, differentiation, de-differentiation, apoptosis, and necrosis of target cells It is known.
- Exosomes contain specific genetic material and bioactivity factors depending on the nature and condition of the derived cells.
- the proliferating stem cell-derived exosomes regulate cell behavior such as cell migration, proliferation and differentiation, and reflect the characteristics of stem cells involved in tissue regeneration (Nature Review Immunology 2002 (2) 569-579).
- the inventors of the present invention have developed an exosomic kit for transcutaneous permeation enhancement of exosomes which greatly promotes transdermal permeation of exosomes while repeatedly studying the new application fields of exosomes and medical or cosmetic techniques Thus completing the present invention.
- It is an object of the present invention to provide an exosome kit for enhancing transcutaneous permeation of exosomes comprising a mask pack, a mask sheet or a patch applied or immersed with a composition containing an exosome as an active ingredient, and an iontophoresis device, .
- the present invention provides a method for treating a transplant of an exosomes comprising an iontophoresis device and a mask pack, a mask sheet or a patch, on which a composition containing an exosome as an active ingredient is applied or immersed, Thereby providing an exosome kit for enhancing permeability.
- exosomes refers to an endoplasmic reticulum of several tens to several hundred nanometers (preferably about 30 to 200 nm) in size, consisting of double lipid membranes identical in structure to the cell membrane The particle size of the exosome can be varied according to the cell type, the separation method and the measurement method) (Vasiliy S. Chernyshev et al., "Size and shape characterization of hydrated and desiccated exosomes", Anal Bioanal Chem, DOI 10.1007 / s00216-015-8535-3). Exosomes contain proteins called exosomal cargo (cargo), nucleic acids (mRNA, miRNA, etc.).
- Exosomal cargo contains a wide range of signaling factors, which are known to be specific for cell types and differentially regulated by the environment of the secretory cells.
- Exosome is an intercellular signaling mediator that is secreted by the cell, and various cell signals transmitted through it regulate cell behavior including activation, growth, migration, differentiation, de-differentiation, apoptosis, and necrosis of target cells It is known.
- biological solution means a liquid solution of biogenic origin, in which the exosome is dispersed, suspended, precipitated, suspended or mixed, and includes, for example, a cell culture solution, a cell culture supernatant, Cell culture supernatant, whole blood, serum, cord blood, plasma, multiple fluid, brain and cerebrospinal fluid, placenta extract, and bone marrow aspirate.
- a cell culture solution a cell culture supernatant, Cell culture supernatant, whole blood, serum, cord blood, plasma, multiple fluid, brain and cerebrospinal fluid, placenta extract, and bone marrow aspirate.
- a “ biological solution” may be cultured or incubated under conditions that release and / or secrete exosomes, and may be frozen and thawed.
- exosome is intended to mean an exosome that is secreted from cells of various animals, plants, bacteria, fungi, algae and the like, preferably stem cells, (E. G., Exosome-like vesicles) having a nano-sized bezacl structure and a composition similar to exosome.
- exosome used in the present invention can be applied to skin and various exosomes which are used in the art or can be used in the future can be used as long as they do not cause adverse effects on the human body. Therefore, it should be understood that the exosome isolated according to the separation method of the following embodiments should be understood as an example of exosome that can be used in the present invention, and the present invention is not limited thereto.
- the term " improvement of skin condition" is a positive change visually and / or tactually perceptible to the appearance and / or feel of the skin, including skin tissue regeneration, Improving the skin condition, preventing aging of the skin, or restoring the skin condition to a mild condition, an improvement condition or a normal condition.
- the term " improvement of skin condition" refers to alleviation, improvement or elimination of skin defects, skin wrinkles, reduced skin elasticity, wrinkles, wrinkles, rough and deep wrinkles, cracks, bumps, ; Skin thickening (e.g., removal of the epidermis, dermis, subcutaneous layer, nail and stratum corneum of the skin); Prevention of skin or hair elasticity loss due to loss, damage and / or inactivation of functional skin elastin; Reduction of cellulite; Discoloration of pale skin, spots, freckles, dullness, skin, hair or nails, such as blackness, dark circles under eyes, erythema, dots, café aureus, becker spots, osteoblast, pigmentary nevus, epidermal nevus, melanin pigment spot Alleviating, improving or eliminating pigmentation, capillary vasodilation or discoloration caused by spider blood vessels; Alleviating or preventing skin dryness and brittleness.
- Skin thickening e.g., removal of the epider
- the term " skin aesthetic" is intended to reduce, alleviate, or ameliorate skin aging such as skin sagging, dented cheeks, depressed eyes, wrinkles, reduced skin elasticity, Restoring the skin condition to a normal state; Skin, skin regeneration, skin whitening, freckles, dark circles, spots, tattoos, acne, elastin layer marks, stretch marks, scarring, enlarged pores, pale, spots, black circles, dark circles, erythema, Removal or correction of various skin defects such as spots, osteoblasts, pigmented nevi, epidermal nevus, melanin pigment spots, and pigmentation; Hair loss enhancement, scalp management, cellulite reduction, facial reduction, contour correction, soft tissue defect correction, tissue enlargement, volume-up, skin swelling, skin moisturizing and soothing, redness and blood vessels Reduction or improvement of diabetes mellitus.
- skin beauty is not limited to the above, and includes, for example, removing or correcting various skin imperfections.
- the term "treatment of skin diseases" refers to the treatment of facial flushing, spots, freckles, dullness, dark circles, dark circles, erythema, dots, café au lait, becker dots, Or ameliorating or alleviating pigmented skin lesions such as pigmentation, or restoring skin conditions that are deteriorated by such pigmented skin lesions to a normal state; Relieving, alleviating or ameliorating vascular skin lesions such as flame nevus, capillary vasodilatation, injection, hemangiomas, vesicular blebs, etc., or to restore normalized skin conditions deteriorated by such vascular skin lesions; Such as contact dermatitis, irritant contact dermatitis, allergic contact dermatitis, phototoxic and photoallergic contact dermatitis, contact urticaria, atopic dermatitis, seborrheic dermatitis, self-sensitizing dermatitis, autoimmune progesterone dermatitis, dermatiti
- iontophoresis refers to a method in which an ionized active ingredient is allowed to permeate through the skin by an electrical repulsive force by applying a minute current to the skin to which the effective substance is applied, .
- the iontophoresis used in one embodiment of the present invention is a method in which a current flows from an external power source to an electrode patch on the skin to introduce minute current into the skin, A method in which minute current is introduced, a method in which minute current is introduced into skin through a patch equipped with a reversed electrodialysis means for generating current through a difference in ion concentration between a high concentration electrolyte solution and a low concentration electrolyte solution, and the like .
- the present invention is not limited thereto, and it is needless to say that various types of iontophoresis can be used.
- An exosome kit for transcutaneous permeation enhancement of exosome comprises a first mask pack, a mask sheet or a patch which is applied or immersed with a composition containing an exosome as an active ingredient, And an iontophoresis device for applying a microcurrent to the skin of the skin.
- an exosome kit for transcutaneous permeation enhancement of an exosome is characterized in that the first mask pack, the mask sheet or the patch is brought into contact with or attached to the skin of the mammal, By placing the iontophoresis device on a mask sheet or patch, the first mask pack, mask sheet or patch can be contacted or attached to be used in such a way that a microcurrent is applied to the skin of the mammal to which the composition is applied.
- the composition may be used in combination with a conventionally used skin improving agent and / or moisturizer to the extent that the action thereof (improvement of skin condition, treatment of skin condition, skin disease, etc.) is not impaired.
- the composition may be supported on or mixed with at least one of hydrogel, hyaluronic acid, hyaluronic acid salt (for example, sodium hyaluronate), or hyaluronic acid gel.
- the type of the hydrogel is not limited, but it may preferably be a hydrogel obtained by dispersing a gelated polymer in a polyhydric alcohol.
- the gel polymer is at least one selected from the group consisting of pluronic, purified agar, agarose, gellan gum, alginic acid, carrageenan, cacao gum, xanthan gum, galactomannan, glucomannan, pectin, cellulose, guar gum and locust bean gum
- the polyhydric alcohol may be at least one selected from the group consisting of ethylene glycol, propylene glycol, 1,3-butylene glycol, isobutylene glycol, dipropylene glycol, sorbitol, xylitol and glycerin.
- the iontophoresis device for enhancing transdermal permeation of exosome comprises a flexible battery, a lithium ion secondary battery, an alkaline battery, a dry battery, a mercury battery, a lithium battery, a nickel-cadmium A battery, and a reverse electrodialysis cell, or a second mask pack, a mask sheet, or a patch having the at least one battery mounted thereon.
- the second mask pack, the mask sheet or the patch may be laminated on the first mask pack, the mask sheet or the patch.
- At least one surface of the first mask pack, mask sheet or patch is coated with a hydrogel, hyaluronic acid, hyaluronate (for example, Sodium hyaluronate), or hyaluronic acid gel.
- a hydrogel hyaluronic acid, hyaluronate (for example, Sodium hyaluronate), or hyaluronic acid gel.
- the type of the hydrogel is not limited, but it may preferably be a hydrogel obtained by dispersing a gelated polymer in a polyhydric alcohol.
- the gelled polymer and the polyhydric alcohol may be exemplified in the above description.
- a micro current flows from the iontophoresis device so that the exosomes can effectively penetrate the epidermis and penetrate deeply into the skin.
- the transdermal permeation enhancement method of exosome in one embodiment of the present invention can be carried out using the exosome kit as described above.
- a method for enhancing transdermal permeability of an exosome comprises the steps of: (a) applying a first mask pack, a mask sheet or patch on which a composition comprising an exosome as an active ingredient is applied or immersed, (B) placing the iontophoresis device on the first mask pack, mask sheet or patch, and (c) contacting the first mask pack, mask sheet or patch with the first mask pack, (D) delivering the exosomes through the microcurrent to the interior of the mammalian skin.
- At least one surface of the first mask pack, mask sheet or patch is coated with a hydrogel, hyaluronic acid, hyaluronic acid salt (for example, sodium hyaluronate ), Or hyaluronic acid gel.
- a hydrogel hyaluronic acid, hyaluronic acid salt (for example, sodium hyaluronate ), Or hyaluronic acid gel.
- the type of the hydrogel is not limited, but it may preferably be a hydrogel obtained by dispersing a gelated polymer in a polyhydric alcohol.
- the gelled polymer and the polyhydric alcohol may be exemplified in the above description.
- the iontophoresis device may be a flexible battery, a lithium ion secondary battery, an alkaline battery, a dry battery, a mercury battery, a lithium battery, a nickel- An electrodialysis cell, or a second mask pack, a mask sheet, or a patch with the at least one battery mounted thereon.
- the step (b) may be performed by laminating the second mask pack, the mask sheet or the patch on the first mask pack, the mask sheet or the patch.
- the exosome can be obtained by performing the following steps: (a) adding trehalose to the biological solution, (b) adding the trehalose (C) separating the exosomes from the filtered biological solution using TFF (Tangential Flow Filtration), and (d) removing the buffer used for desalting and buffer exchange (diafiltration). , Adding trehalose to the solution, and performing desalting and buffer exchange (diafiltration) on the separated exosome using TFF (Tangential Flow Filtration) using the buffer solution to which the trehalose is added .
- TFF Tangential Flow Filtration
- exosomes having a uniform particle size distribution and high purity can be effectively obtained (FIGS. 6A to 6C) 6E).
- trehalose in the pre-filtration step (step (b) before exocase separation by TFF) and desalting by TFF and buffer exchange step (step (d)) after separation of exosome, a high purity particle size distribution Uniform exosome can be obtained with high yield.
- Trehalose provides the ability to efficiently isolate exosomes for impurities such as cellular debris, waste products, proteins and macromolecules.
- the desalting and buffer exchange can be performed continuously or intermittently. Desalting and buffer exchange can be carried out using a buffer solution having a volume of at least 4 times, preferably 6 times to 10 times, more preferably 12 times the starting volume.
- a molecular weight cutoff (MWCO) 100,000 Da (Dalton), 300,000 Da, 500,000 Da or 750,000 Da TFF filter or 0.05 ⁇ ⁇ TFF filter can be used.
- the step (c) may further include a step of concentrating the solution to a volume of 1/100 to 1/25 using TFF (Tangential Flow Filtration).
- the biological solution may be a stem cell culture solution.
- the type of the stem cell is not limited, but may be a mesenchymal stem cell, for example, a fat, a bone marrow, an umbilical cord or a cord blood-derived stem cell, more preferably a fat-derived stem cell.
- the type of the adipose-derived stem cell is not limited as long as it does not cause a risk of infection by a pathogen and does not cause an immune rejection reaction, but it may be preferably a human adipose-derived stem cell.
- the exosome used in the present invention is not limited to the exosome obtained according to the separation method described above, and it is needless to say that various exosomes which are used in the art or can be used in the future can be used. It is to be understood that the exosome isolated according to the above separation method should be understood as an example of exosome that can be used in the composition of the present invention, and the present invention is not limited thereto.
- conditioning of the skin means improvement of the condition of the skin and / or prevention of the condition of the skin
- improvement of the condition of the skin means visual and / Or a tactile perceptible positive change.
- skin condition improvement may include skin regeneration, wrinkle removal or improvement, whitening, scar removal, skin texture improvement, redness reduction, moistening or smoothing of the condition of the skin, Rubbing can be an improvement of the deteriorated skin condition.
- a method for enhancing transdermal permeation of an exosome comprising the steps of: (a) performing a transcutaneous permeation enhancing method of exosome as described above; and (b) The method comprising the steps of:
- the present invention has the effect of facilitating skin application of exosomes that can function as functional cosmetics or medicines, and penetrating deeply into the skin while allowing the exosomes to pass the skin barrier effectively. Therefore, the present invention can be applied to a skin beauty which improves a poor skin condition or restores to a normal state, and can exhibit an excellent effect. In addition, the present invention provides an effect of treating a skin disease which alleviates, It is possible to exhibit an excellent effect.
- FIG. 1 is a flow chart illustrating a process for separating and purifying exosomes in a method for producing exosomes from a biological solution according to one embodiment of the present invention.
- FIG. 2 is a graph showing a result of measuring a relative amount of protein contained in a solution for each step of preparing a biological solution, for example, a stem cell culture solution, according to an embodiment of the present invention .
- the ratio of the total amount of protein in each step was expressed by the relative ratio of total protein amount to the total biological solution.
- the experimental results show the results obtained in two different batches, respectively.
- FIG. 3 shows the results of measuring the productivity and purity of exosomes obtained according to one embodiment of the present invention.
- the productivity of exosomes was calculated as "the number of particles of exosome obtained per mL of biological solution, eg, a stem cell culture (CM),” and the purity of exosome was calculated as "the number of exosomes per microgram of protein contained in the final fraction Quot; number of particles "
- the experimental results show the results obtained in five different batches.
- 4A to 4E show results of physical property analysis of exosomes obtained according to one embodiment of the present invention.
- 4A shows particle size distribution and number of particles by TRPS (tunable resistive pulse sensing) analysis.
- Figure 4B shows particle size distribution and number of particles by NTA (nanoparticle tracking analysis) analysis.
- 4C shows particle images by transmission electron microscopy (TEM) according to magnification.
- 4D shows the Western blot results of exosomes obtained according to one embodiment of the present invention.
- &Quot; Figure 4E shows flow cytometric analysis results for CD63 and CD81 in marker assays for exosomes obtained according to one embodiment of the present invention.
- Figures 5A-5C show the results of NTA analysis on particle size distribution showing that a uniform and high-purity exosome is obtained with trehalose addition. As the amount of trehalose added increases, a particle size distribution having a single peak can be obtained.
- 6A to 6C show results of NTA analysis showing particle size distribution according to whether trehalose was added in the process of producing exosome according to one embodiment of the present invention.
- 6A shows a case where trehalose is added throughout the production process
- Fig. 6B shows a case where trehalose is added after the cell culture solution is stored in a frozen state
- the results are shown without adding os.
- 6D shows the results of comparing relative productivity and relative concentration of exosomes isolated by the methods of FIGS. 6A to 6C.
- 6E shows the mean size of exosomes isolated by the methods of FIGS. 6A to 6C.
- FIG. 7 shows the result of confirming the absence of cytotoxicity after treatment of exosome according to one embodiment of the present invention with HS68 cells of human skin fibroblasts.
- FIG. 8 shows fluorescence intensity measurement results of exosomes stained with PKH67.
- Fig. 9 is an image of a fluorescence microscope confirming the degree of transfer of fluorescent stained exosomes into pig skin tissue.
- FIG. 10 is a confocal fluorescence microscope image showing the degree of fluorescence-stained exosomes transferred into the mouse skin tissue.
- FIG. 11 is a graph showing a comparison of the total fluorescence intensity obtained by measuring the fluorescence intensity on each image in Fig.
- FIG. 12 is a perspective view showing a configuration of the exosomes kit 100 according to one embodiment of the present invention.
- FIG. 13 is a photograph showing the skin condition before and after treatment of human skin with the exosomal kit of the present invention.
- FIG. 14 is a graph showing the results of application of iontophoresis for applying a microcurrent to a skin (affected part) coated with the composition after applying the composition containing exosome used in the exosome kit of the present invention to human skin As a result, it is a photograph showing that erythema of the skin (lesion) is remarkably improved.
- FIG. 15 is a photograph showing the skin condition before and after the treatment of the exosome kit of the present invention on the face of a person suffering from acne;
- 16A to 16I show the results of improving skin wrinkles, improving skin elasticity, skin moisturizing and dermal density when the exosome kit of the present invention is applied to human skin.
- HS68 cells a human dermal fibroblast, were purchased from ATCC and cultured in RPMI 1640 supplemented with 10% fetal bovine serum (purchased from ThermoFisher Scientific) and 1% antibiotic-antimycotics (purchased from ThermoFisher Scientific) The cells were subcultured in DMEM (purchased from ThermoFisher Scientific) medium containing 5% CO 2 at 37 ° C.
- adipose-derived stem cells were cultured at 5% CO 2 and 37 ° C. Then, the cells were washed with a phosphate-buffered saline (purchased from ThermoFisher Scientific), replaced with serum-free, non-phenol red medium, cultured for 1 to 10 days, and the supernatant .
- a phosphate-buffered saline purchased from ThermoFisher Scientific
- Trehalose was added to the culture medium in an amount of 2% by weight in order to obtain an exosome having a uniform particle size distribution and high purity in the process of separating exosome.
- the culture was filtered with a 0.22 ⁇ m filter to remove impurities such as cellular debris, waste products and large particles.
- the filtered cultures were immediately separated to isolate exosomes.
- the filtered culture was stored in a refrigerator (image below 10 ° C) and used for exosome isolation.
- the filtered culture was frozen in an ultra-low temperature freezer at -60 ° C or lower, and thawed, followed by exosome isolation. Then, the exosomes were separated from the culture medium by using Tangential Flow Filtration (TFF).
- TMF Tangential Flow Filtration
- Example 1 a TFF (Tangential Flow Filtration) method was used for separating, concentrating, desalting and diafiltration exosomes from a culture filtrated with a 0.22 ⁇ m filter.
- a cartridge filter also called a hollow fiber filter (purchased from GE Healthcare) or a cassette filter (purchased from Pall or Sartorius or Merck Millipore) was used.
- the TFF filter can be selected by a variety of molecular weight cutoffs (MWCO). Exosomes were selectively isolated and concentrated by selected MWCOs, and particles, proteins, lipids, nucleic acids, low molecular weight compounds, etc. smaller than MWCO were removed.
- MWCO molecular weight cutoffs
- TFF filters of MWCO 100,000 Da (Dalton), 300,000 Da, or 500,000 Da were used.
- the culture medium was concentrated to a volume of about 1/100 to 1/25 using the TFF method, and substances smaller than MWCO were removed to separate the exosomes.
- Separated and concentrated exosomal solutions were further desalted and buffered (diafiltration) using the TFF method.
- the desalination and buffer exchange are performed by continuous diafiltration or discontinuous diafiltration, and at least 4 times, preferably 6 times to 10 times or more, more preferably, Was performed using a buffer solution having a volume of 12 times or more.
- 2% by weight of trehalose dissolved in PBS was added to obtain an exosome having a uniform particle size distribution and high purity.
- 6A to 6E show the effect of obtaining an exosome having a high purity and a uniform particle size distribution with trehalose treatment at a high yield.
- the amount of protein in the fractions of the isolated exosome, culture medium, and TFF separation process was measured using BCA colorimetry (purchased from ThermoFisher Scientific) or FluoroProfile fluorescence (purchased from Sigma).
- BCA colorimetry purchased from ThermoFisher Scientific
- FluoroProfile fluorescence purchased from Sigma.
- the extent to which the exosome was isolated and concentrated by the TFF method of the present invention and the removal of proteins, lipids, nucleic acids, and low-molecular compounds was monitored by a protein determination method, and the results are shown in FIG. As a result, it was found that the protein present in the culture solution was very effectively removed by the TFF method of one embodiment of the present invention.
- FIG. 3 shows the results of comparing the productivity and purity in five independent batches when isolating exosomes by the TFF method of one embodiment of the present invention. As a result of analyzing the results obtained from the five independent batches, it was confirmed that the exosome can be separated very stably by the TFF method of one embodiment of the present invention.
- 5A to 5C show results of NTA analysis of the size distribution of exosome according to whether or not trehalose was added after the exosome was separated by the TFF method.
- concentration of trehalose was increased to 0% by weight, 1% by weight and 2% by weight (from top to bottom of FIGS. 5A to 5C) and repeated three times.
- particles having a size of 300 nm or more were identified, while particles having a size of 300 nm or more were reduced by increasing the amount of trehalose, and the size distribution of the exosome was uniformized .
- FIG. 4D shows the presence of CD9, CD63, CD81 and TSG101 markers as a result of performing Western blotting on isolated exosomes according to the method of one embodiment of the present invention.
- Anti-CD9 purchased from Abcam
- anti-CD63 purchasedd from System Biosciences
- anti-CD81 purchasedd from System Biosciences
- anti-TSG101 purchasedd from Abcam
- FIG. 4E shows the presence of CD63 and CD81 markers as a result of analysis using a flow cytometer on exosomes isolated according to the method of one embodiment of the present invention.
- Human CD63 isolation / detection kit purchased from ThermoFisher Scientific
- PE-mouse anti-human CD63 PE-Mouse anti markers were stained using the PE-mouse CD63 (purchased from BD) and PE-mouse anti-human CD81 (purchased from BD), and analyzed using a flow cytometer (ACEA Biosciences) Respectively.
- exosome used in the present invention is not limited to the exosome of the above-mentioned embodiments, and it is needless to say that various exosomes which are used in the art or can be used in the future can be used. It should be understood that the exosome isolated according to the above embodiments is an example of exosome that can be used in the present invention, and the present invention is not limited thereto.
- exosomes were treated by concentration to the cells and the proliferation rate of the cells was confirmed.
- HS68 cells were suspended in DMEM containing 10% FBS, and the cells were mixed with 80 ⁇ 90% confluency and cultured in a 5% CO 2 incubator at 37 ° C for 24 hours. After 24 hours, the culture solution was removed, and the cell survival rate was evaluated by culturing the exosome prepared in Example 2 for each concentration and culturing for 24 to 72 hours.
- WST-1 reagent purchased from Takara
- MTT reagent purchased from Sigma
- CellTiter-Glo reagent purchased from Promega
- Aramar Blue reagent alamarBlue reagent purchased from ThermoFisher Scientific
- a microplate reader purchased from Molecular Devices
- the comparison group was based on the number of cells cultured in the normal cell culture medium not treated with exosome, and it was confirmed that no cytosoxicity by exosome was observed within the tested concentration range (FIG. 7).
- PKH67 dye (purchased from Sigma) was used to prepare fluorescently stained exosomes. 1 mM PKH67 was diluted in Diluent C (purchased from Sigma) to prepare a 10 ⁇ M PKH67 solution, mixed with an appropriate concentration of exosome solution, and allowed to react at room temperature for 10 minutes in the absence of light. After the reaction, an MW3000 spin column (purchased from ThermoFisher Scientific) was used to remove the remaining PKH67 dye from the exosomes stained with PKH67 (hereinafter abbreviated as "PKH-exosomes").
- Example 6 Skin permeability test of exosome used in the exosome kit of the present invention
- PKH-exosomes were dispersed in phosphate buffer (PBS) at a proper concentration, for example, 1 ⁇ 10 5 to 1 ⁇ 10 9 particles / mL, and then applied to the outer surface of the pig skin.
- PBS phosphate buffer
- the nonwoven fabric was covered and allowed to react for an appropriate period of time, for example, 30 minutes to 1 hour to allow the PKH-exosomes to be delivered to the subcutaneous tissues.
- the PKH-exosomes were applied to the outer surface of the pig skin and covered with the nonwoven fabric, followed by flowing a microcurrent for a predetermined time, for example, 30 minutes to 1 hour.
- the pig skin tissue was immersed in a 3.7% formaldehyde solution, reacted overnight, and washed three times for 5 minutes each with phosphate buffered saline.
- the washed pig skin tissue was immersed in a 30% sucrose solution and treated with OCT compound.
- sections were prepared on a longitudinal section using a microtome, and tissue sections were placed on a slide glass.
- the preparation of the tissue section may be carried out before the tissue is fixed with formaldehyde solution. Fluorescence detected from PKH-exosomes in tissue sections was observed using fluorescence microscopy.
- PKH-exosomes transmitted to the subcutaneous tissue through the epidermis of the pig skin tissue were identified.
- the exosomes were more effectively passed through the epidermis, deeply transferred into the skin tissue, and more effectively absorbed to the skin when active current was delivered (active transdermal delivery) (see FIG. 9).
- the exosomes used in the exosome kit of the present invention can effectively pass through the epidermis and be deeply transferred into the skin tissue, and can be effectively absorbed to the skin.
- PKH-exosomes were dispersed in phosphate buffer (PBS) at a proper concentration, for example, 1 ⁇ 10 5 to 1 ⁇ 10 9 particles / mL, and then applied to the outside of the skin tissue of the mice.
- PBS phosphate buffer
- the nonwoven fabric was pre-positioned outside the mouse skin tissue, and PKH-exosomes were injected between the nonwoven fabric and skin tissue. Then, the reaction was carried out for 30 minutes to 1 hour.
- the PKH-exosomes were injected between the nonwoven fabric and the skin tissue, and the microcurrent was flowed for a predetermined time, for example, 30 minutes to 1 hour. After completion of the reaction, the PKH-exosomes transferred into the skin tissue were confirmed immediately using a confocal fluorescence microscope (Leica, SP8X) or the skin tissue and the PKH-exosomal solution were further reacted for 1 hour to 6 hours , And PKH-exosomes were identified by confocal fluorescence microscopy. As a result, it was confirmed that the exosomes were more efficiently passed through the epidermis and deeply transferred into the skin tissue when the microcurrent was passed (active transdermal delivery), and more effectively absorbed to the skin (Figs. 10 and 11) .
- the exosome kit 100 includes a liquid immersion sheet mask 10 (a white sheet mask coated or immersed with a composition containing the exosome prepared in Example 2) And a percutaneous permeation promoting sheet mask (silver sheet mask) 20 which is an iontophoresis device.
- Exosome 12 is coated or deposited on the surface or inside of liquid immersion sheet mask 10.
- a battery 22 for generating a microcurrent is mounted on the percutaneous permeation enhancing sheet mask 20 and a conductive pattern 24 electrically connected to the cell 22 is attached to the percutaneous permeation enhancing sheet mask 20, So that the micro current generated from the battery 22 can be uniformly transmitted to the entirety of the percutaneous permeation enhancing sheet mask 20.
- the conductive pattern 24 is formed by printing or plating a conductive metal such as gold, silver, or copper.
- exosome kit 100 having the above-described structure is applied once to the face of a person having a flushing symptom and a severe skin trouble (hereinafter referred to as "case 1") to alleviate or alleviate skin troubles and flushing symptoms .
- case 1 a severe skin trouble
- exosome kit 100 of the present invention was applied once to the face of a person with flushing symptom (hereinafter referred to as " case 2 ") to evaluate whether the overall skin tone and flushing symptom were improved.
- a liquid immersion sheet mask 10 containing 5 ⁇ 10 5 exosomes 12 was uniformly adhered to the entire faces of the cases 1 and 2 by aligning them with the eyes and mouth parts and then a microcurrent of about 0.3 to 0.4 mA
- An activated percutaneous permeation enhancing sheet mask 20 which was activated to flow was laminated on the liquid immersion sheet mask 10 and used for about 25 to 30 minutes.
- the exosomatic kit 100 of the present invention which comprises the liquid immersion sheet mask 10 on which the composition containing the exosome as an active ingredient is immersed and the percutaneous permeation promoting sheet mask (iontophoresis device) 20, It can be said that there is a skin-beauty effect or a skin disease treatment effect that prevents, suppresses, alleviates or improves symptoms and skin troubles.
- a composition (exosome suspension) containing the exosome prepared in Example 2 at a concentration of 0.29 x 10 8 particles / mL was applied to the affected part (hand, neck, arm, etc.) of three severe atopic patients complaining of itching
- An iontophoresis was performed using a iontophoresis device (IONZYME DF MACHINE) (purchased from Environ) to flow a micro current of 0.4 mA for 20 minutes to the affected part of the composition.
- IONZYME DF MACHINE purchased from Environ
- the exosome kit 100 of the present invention can be said to have a skin-beauty effect or a skin disease-treating effect for preventing, suppressing, alleviating or alleviating itching and erythema of the skin as confirmed by the clinical test as described above.
- Example 8 Treatment of exosome kit on facial surface of subjects with acne symptoms
- Example 7 The "exosome kit" described in Example 7 was applied to the face of a person suffering from acne symptomatically once every four days to evaluate whether acne symptoms and related skin troubles were alleviated or improved.
- a liquid immersion sheet mask 10 containing 5 ⁇ 10 5 exosomes 12 was applied to the entire face of a person suffering from acne symptomatically by aligning them with the eyes and the mouth and then a micro current of about 0.3 to 0.4 mA
- An activated percutaneous permeation enhancing sheet mask 20 is laminated on the liquid immersion sheet mask 10 and used for about 25 to 30 minutes.
- the exosome kit 100 of the present invention can be said to have a skin-beauty effect or a skin disease treatment effect for preventing, suppressing, alleviating or alleviating acne symptoms and skin troubles associated therewith.
- Example 9 Test for improving wrinkles, improving elasticity, moisturizing effect, etc. on human skin
- the exosomes prepared in Example 2 were mixed at a concentration of 1 x 10 < 7 > (Translucent oil-in-water) and the exosome kit 100 of the present invention were used once every three days in the evening to test skin cosmetic effects such as skin wrinkles, skin elasticity improvement, moisturizing and skin regeneration effects.
- the liquid immersion sheet mask 10 was brought into close contact with the eyes and the mouth, and the entire surface of the face was evenly adhered. Then, an activated percutaneous permeation- The mask 20 was laminated on the liquid immersion sheet mask 10 and used for about 25 to 30 minutes.
- the skin moisturizing effect was measured by a moisture meter (Corneometer CM825) (Courage-Khazaka eletronic GmbH, Germany) And skin elasticity was evaluated by measuring the sound pressure with CM580 (Cutometer CM580) (Courage + Khazaka electronic GmbH, Germany).
- CM580 Cutometer CM580
- Dermal density improvement was assessed by analyzing the density (%) after the skin scanner ultrasonography at the eye.
- the test subjects were tested for the test items after the use of the exosomatic kit 100 of the present invention in five steps of excellent (4), good (3), normal (2), poor (1) and very poor (0) And responded to the questionnaire.
- the questionnaire survey the mean value and the standard deviation of the questionnaire and the percentage of the subjects to the answer were obtained for each test item.
- 100% of the test subjects were evaluated as above all the test items.
- the subjects were asked to answer the questionnaire about feeling of use of the exosome kit (100) of the present invention.
- the exosome kit 100 of the present invention is excellent in skin wrinkles, skin elasticity, skin regeneration and skin moisturizing effects, as confirmed by the above-mentioned clinical tests.
Abstract
Description
시험항목Test Items | 4주후(%)After 4 weeks (%) | 평균(%)Average(%) | 평균대비Average contrast |
눈가주름Eye wrinkles | -5.647-5.647 | -7~-5-7 to -5 | 평균Average |
팔자주름Wrinkles | -7.415-7.415 | -5-5 | 좋음good |
입가주름Wrinkles | -6.694-6.694 | -7-7 | 평균Average |
피부수분함유량Skin moisture content | 21.38321.383 | 1010 | 매우좋음Very good |
피부탄력Skin elasticity | 9.2919.291 | 5-65-6 | 좋음good |
눈꼬리리프팅Eyebrow lifting | 16.34216.342 | 1010 | 좋음good |
볼리프팅Ball lifting | -12.053-12.053 | -10-10 | 좋음good |
입꼬리리프팅Lifting a mouthpiece | 22.85122.851 | 1010 | 매우좋음Very good |
진피치밀도Dermal density | 19.71519.715 | 15-2015-20 | 평균Average |
Claims (9)
- 엑소좀을 유효성분으로 포함하는 조성물이 도포되거나 침적된 제1 마스크팩, 마스크시트 또는 패취와, A first mask pack, a mask sheet or a patch which is applied or deposited with a composition containing an exosome as an active ingredient,상기 조성물이 적용된 포유동물의 피부에 미세전류를 흘려 주는 이온토포레시스 디바이스를 포함하는, 엑소좀의 경피 투과 증진을 위한 엑소좀 키트.An exosomatic kit for enhancing transcutaneous permeation of exosomes, comprising an iontophoresis device for delivering a microcurrent to the skin of a mammal to which said composition is applied.
- 제1항에 있어서,The method according to claim 1,상기 제1 마스크팩, 마스크시트 또는 패취를 포유동물의 피부 위에 접촉 또는 부착시키고, 상기 제1 마스크팩, 마스크시트 또는 패취 위에 상기 이온토포레시스 디바이스를 위치시킴으로써, 상기 제1 마스크팩, 마스크시트 또는 패취가 접촉 또는 부착되어 상기 조성물이 적용된 포유동물의 피부에 미세전류를 흘려 주는 것을 특징으로 하는, 엑소좀의 경피 투과 증진을 위한 엑소좀 키트.Wherein the first mask pack, the mask sheet or the patch is contacted or adhered onto the skin of the mammal, and the iontophoresis device is placed on the first mask pack, the mask sheet or the patch, Or patches are contacted or adhered to flow micro-currents through the skin of a mammal to which said composition is applied. ≪ RTI ID = 0.0 > 8. < / RTI >
- 제1항 또는 제2항에 있어서,3. The method according to claim 1 or 2,상기 이온토포레시스 디바이스는 가요성 배터리, 리튬이온 이차 전지, 알칼리 전지, 건전지, 수은 전지, 리튬 전지, 니켈-카드뮴 전지, 및 역전기 투석 전지로 구성된 군으로부터 선택된 적어도 1종의 전지를 포함하거나, 상기 적어도 1종의 전지가 장착된 제2 마스크팩, 마스크시트 또는 패취인, 엑소좀의 경피 투과 증진을 위한 엑소좀 키트.The iontophoresis device includes at least one battery selected from the group consisting of a flexible battery, a lithium ion secondary battery, an alkaline battery, a dry battery, a mercury battery, a lithium battery, a nickel-cadmium battery, , A second mask pack, a mask sheet, or a patch, on which at least one kind of battery is mounted, the exosome kit for enhancing transcutaneous permeation of exosomes.
- 제3항에 있어서,The method of claim 3,상기 제1 마스크팩, 마스크시트 또는 패취 위에 상기 제2 마스크팩, 마스크시트 또는 패취가 적층되어 사용되는 것을 특징으로 하는, 엑소좀의 경피 투과 증진을 위한 엑소좀 키트.Wherein the second mask pack, the mask sheet, or the patch is laminated on the first mask pack, the mask sheet or the patch, and is used for the transcutaneous permeation enhancement of the exosome.
- (a) 엑소좀을 유효성분으로 포함하는 조성물이 도포되거나 침적된 제1 마스크팩, 마스크시트 또는 패취를 포유동물의 피부 위에 접촉 또는 부착하는 단계와,(a) contacting or adhering a first mask pack, a mask sheet or a patch, onto which a composition comprising an exosome as an active ingredient is applied or deposited, onto the skin of the mammal,(b) 상기 제1 마스크팩, 마스크시트 또는 패취 위에 이온토포레시스 디바이스를 위치시키는 단계와, (b) positioning the iontophoresis device on the first mask pack, mask sheet or patch,(c) 상기 제1 마스크팩, 마스크시트 또는 패취가 접촉 또는 부착되어 상기 조성물이 적용된 포유동물의 피부에 미세전류를 흘려 주는 이온토포레시스를 수행하는 단계와, (c) performing iontophoresis, wherein the first mask pack, mask sheet or patch is contacted or adhered to flow a microcurrent into the skin of the mammal to which the composition is applied;(d) 상기 미세전류를 통하여 상기 엑소좀을 포유동물 피부 내부로 전달하는 단계를 포함하는, 엑소좀의 경피 투과 증진 방법.(d) delivering the exosome through the microcurrent to the interior of the mammalian skin.
- 제5항에 있어서,6. The method of claim 5,상기 이온토포레시스 디바이스는 가요성 배터리, 리튬이온 이차 전지, 알칼리 전지, 건전지, 수은 전지, 리튬 전지, 니켈-카드뮴 전지, 및 역전기 투석 전지로 구성된 군으로부터 선택된 적어도 1종의 전지를 포함하거나, 상기 적어도 1종의 전지가 장착된 제2 마스크팩, 마스크시트 또는 패취인, 엑소좀의 경피 투과 증진 방법.The iontophoresis device includes at least one battery selected from the group consisting of a flexible battery, a lithium ion secondary battery, an alkaline battery, a dry battery, a mercury battery, a lithium battery, a nickel-cadmium battery, , A second mask pack, a mask sheet or a patch, on which the at least one kind of battery is mounted.
- 제6항에 있어서,The method according to claim 6,상기 (b) 단계는 상기 제1 마스크팩, 마스크시트 또는 패취 위에 상기 제2 마스크팩, 마스크시트 또는 패취를 적층하여 수행되는, 엑소좀의 경피 투과 증진 방법.Wherein the step (b) is performed by laminating the second mask pack, the mask sheet or the patch on the first mask pack, the mask sheet or the patch.
- (a) 제5항 내지 제7항 중 어느 한 항에 기재된 엑소좀의 경피 투과 증진 방법을 수행하는 단계와, (b) 상기 (a) 단계를 통해 피부 상태를 개선시키는 단계를 포함하는, 치료용을 제외한 포유동물 피부의 상태를 조절하는 미용방법.(a) performing the transdermal patch enhancement method of exosome according to any one of claims 5 to 7, and (b) improving the skin condition through the step (a). A cosmetic method for regulating the condition of a mammal skin except a dragon.
- (a) 제5항 내지 제7항 중 어느 한 항에 기재된 엑소좀의 경피 투과 증진 방법을 수행하는 단계와,(a) performing the transdermal permeation enhancing method of exosome according to any one of claims 5 to 7;(b) 상기 (a) 단계를 통해 피부질환의 병적상태를 완화, 개선 내지는 정상상태로 회복시켜 주는 단계를 포함하는, 피부질환 치료방법.(b) treating the skin disease by relaxing, ameliorating or restoring the pathological condition of the skin disease through the step (a).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0143358 | 2017-10-31 | ||
KR20170143358 | 2017-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019088545A1 true WO2019088545A1 (en) | 2019-05-09 |
Family
ID=66333242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/012549 WO2019088545A1 (en) | 2017-10-31 | 2018-10-23 | Exosome kit and method for enhancing transdermal permeation of exosomes by using same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102320845B1 (en) |
WO (1) | WO2019088545A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102347311B1 (en) * | 2019-03-11 | 2022-01-06 | 바이오센서연구소 주식회사 | Device using reversed electrodialysis and redox activity, and method for delivering drug using the same |
KR102565365B1 (en) * | 2022-01-24 | 2023-08-09 | 주식회사 엑소코바이오 | New composition comprising exosomes derived from Nepeta cartaria as an active ingredient |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100628946B1 (en) * | 2005-04-04 | 2006-09-27 | 주식회사 엘지생활건강 | Mask pack set using minute current |
KR20160086253A (en) * | 2015-01-08 | 2016-07-19 | 한양대학교 에리카산학협력단 | Cosmetic composition containing exosomes extracted from stem cell for skin whitening, antiwrinkle or regeneration |
KR20160116491A (en) * | 2015-03-30 | 2016-10-10 | 조정호 | Iontophoresis mask pack apparatus having patterned conducting carbon film using smart phone |
KR20170044999A (en) * | 2015-10-16 | 2017-04-26 | (주)프로스테믹스 | Composition for improving skin and preventing hairloss and method for preparing the same |
KR20170104821A (en) * | 2016-03-08 | 2017-09-18 | (주)아이보손 | Iontophoresis apparatus for mask pack |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009215934C1 (en) * | 2008-02-22 | 2014-05-08 | Agency For Science, Technology And Research (A*Star) | Mesenchymal stem cell particles |
KR20090111269A (en) * | 2009-02-10 | 2009-10-26 | (주)프로스테믹스 | Composition for preventing or treating atopic dermatitis |
KR101443180B1 (en) | 2012-11-27 | 2014-09-22 | 한국콜마주식회사 | Novel Drug Delivery System for Percutaneous Absorption, Composition for External Preparation Preventing Hair Loss, and Cosmetics Using the Same |
US20160089535A1 (en) * | 2014-09-29 | 2016-03-31 | Elc Management Llc | Targeted And Individualized Delivery Of Skincare Treatments With Micro-Current In A Mask Or Patch Form |
WO2016072821A1 (en) | 2014-11-07 | 2016-05-12 | 한양대학교 에리카산학협력단 | Composition for differentiation induction of adipocyte containing stem cell-derived exosome, regeneration of adipose tissue, and skin whitening or wrinkle improvement |
KR101784050B1 (en) | 2014-12-23 | 2017-10-10 | 영남대학교 산학협력단 | Pharmaceutical composition for preventing or treating cell senescence comprising exosome |
KR101686064B1 (en) | 2015-09-21 | 2016-12-13 | (주)프로스테믹스 | Composition for immunosuppression and anti-inflammation |
WO2017119520A1 (en) * | 2016-01-05 | 2017-07-13 | 바이오센서연구소 주식회사 | Facial mask using reverse electrodialysis and kit comprising same |
-
2018
- 2018-10-23 KR KR1020180126488A patent/KR102320845B1/en active IP Right Grant
- 2018-10-23 WO PCT/KR2018/012549 patent/WO2019088545A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100628946B1 (en) * | 2005-04-04 | 2006-09-27 | 주식회사 엘지생활건강 | Mask pack set using minute current |
KR20160086253A (en) * | 2015-01-08 | 2016-07-19 | 한양대학교 에리카산학협력단 | Cosmetic composition containing exosomes extracted from stem cell for skin whitening, antiwrinkle or regeneration |
KR20160116491A (en) * | 2015-03-30 | 2016-10-10 | 조정호 | Iontophoresis mask pack apparatus having patterned conducting carbon film using smart phone |
KR20170044999A (en) * | 2015-10-16 | 2017-04-26 | (주)프로스테믹스 | Composition for improving skin and preventing hairloss and method for preparing the same |
KR20170104821A (en) * | 2016-03-08 | 2017-09-18 | (주)아이보손 | Iontophoresis apparatus for mask pack |
Also Published As
Publication number | Publication date |
---|---|
KR20190049474A (en) | 2019-05-09 |
KR102320845B1 (en) | 2021-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7037205B2 (en) | Uses for suppressing or ameliorating itching of compositions containing stem cell-derived exosomes as an active ingredient | |
KR102163806B1 (en) | Composition for reducing sebum release comprising an exosome derived from stem cell as an active ingredient | |
WO2019168281A1 (en) | Skin care method using laser beam irradiation on skin and stem cell-derived exosome treatment | |
EP3639832A2 (en) | Use of composition comprising adipose stem cell-derived exosome as effective ingredient in alleviating dermatitis | |
KR102646145B1 (en) | Composition for reducing skin pore size comprising an exosome derived from stem cell as an active ingredient | |
KR20190069301A (en) | Cosmetic composition for preventing, suppressing, alleviating or improving sensitive skin comprising an exosome derived from stem cell as an active ingredient | |
CN110123838B (en) | Resveratrol-loaded human pluripotent stem cell exosome and preparation method and application thereof | |
WO2019182299A1 (en) | Skin care method using ipl radiation on skin and stem cell-derived exosome treatment in combination | |
KR20190003399A (en) | A composition comprising an exosome derived from stem cell as an active ingredient and its application for improving skin fibrosis | |
KR20190003383A (en) | A composition comprising an exosome derived from adipose-derived stem cell as an active ingredient and its application for improving dermatitis | |
KR20190069277A (en) | A composition comprising an exosome and/or extracellular vesicle derived from stem cell as an active ingredient and its application for preventing, suppressing, alleviating or improving sensitive skin | |
WO2019088545A1 (en) | Exosome kit and method for enhancing transdermal permeation of exosomes by using same | |
KR20240037208A (en) | Composition for improving face redness comprising an exosome derived from stem cell as an active ingredient | |
KR20190069291A (en) | Cosmetic composition for moisturizing skin comprising an exosome derived from stem cell as an active ingredient | |
WO2020027467A1 (en) | Lyophilized preparation of stem cell-derived exosomes, and anti-inflammatory composition comprising same as active ingredient | |
WO2019112238A2 (en) | Cosmetic composition for moisturizing skin comprising stem cell-derived exosome as active ingredient | |
KR20190045829A (en) | Method for improving transdermal delivery of exosome and its application | |
WO2019112229A2 (en) | New use of exosome kit comprising exosome derived from stem cell | |
KR20200016183A (en) | Method for skin care using the combination of skin peeling and treating exosomes onto skin | |
KR20200038672A (en) | Method for improving skin condition by spraying and penetrating plasma into skin along with treating exosomes onto skin | |
WO2019190093A1 (en) | Skin care method using, in combination, application of rf energy to skin and stem cell-derived exosome treatment on skin | |
WO2019231133A1 (en) | Composition for reducing pores, comprising stem cell-derived exosomes as active ingredient | |
KR102197562B1 (en) | New use of exosome kit comprising exosomes derived from stem cells | |
KR20190114740A (en) | Method of skin care using the combination of applying radio frequency energy and treating exosome onto skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18874650 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020600104 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18874650 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |